Gabapentin improves cold-pressor pain responses in methadone-maintained patients

Area of Science:

• Pain Management
• Pharmacology
• Addiction Medicine

Background:

• Opioid-induced hyperalgesia (OIH) is observed in patients on methadone maintenance (MM).
• OIH shares neuro-inflammatory and central sensitization mechanisms with neuropathic pain.
• Gabapentin (GPN) is a key pharmacotherapy for neuropathic pain.

Purpose of the Study:

• To evaluate the efficacy of gabapentin (GPN) in reversing opioid-induced hyperalgesia (OIH) in methadone maintenance (MM) patients.
• To assess changes in pain threshold and tolerance with GPN treatment in MM patients.

Main Methods:

• A 5-week double-blind clinical trial was conducted.
• Gabapentin (GPN) was titrated to 2400mg/day.
• Pain threshold and tolerance were measured at peak and trough methadone plasma levels in compliant and abstinent subjects.

Main Results:

• Significant improvements in cold-pressor pain threshold and tolerance were observed.
• Improvements were noted at both peak and trough methadone levels (p<0.05).
• Gabapentin (GPN) was well-tolerated with low dropout rates (2%).

Conclusions:

• Gabapentin (GPN) is effective in decreasing opioid-induced hyperalgesia (OIH) in stable, abstinent methadone maintenance (MM) patients.
• GPN shows promise as a treatment for OIH in this population.
• The findings support GPN's utility beyond neuropathic pain management.